Rigel Pharmaceuticals (RIGL) Cost of Revenue (2018 - 2026)

Rigel Pharmaceuticals' Cost of Revenue history runs 9 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 4.47% year-over-year to $4.6 million; the TTM figure through Mar 2026 stood at $19.8 million (down 5.77% YoY), while the FY2025 annual figure was $19.6 million, up 5.22% from the prior year.
• Cost of Revenue was $4.6 million for Q1 2026 at Rigel Pharmaceuticals, down from $6.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $8.0 million in Q3 2024 to a low of $121000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $3.0 million across 5 years, with a median of $2.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue sank 61.71% in 2022, then surged 1008.19% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $342000.0 in 2022, then soared by 1008.19% to $3.8 million in 2023, then soared by 52.74% to $5.8 million in 2024, then advanced by 2.87% to $6.0 million in 2025, then retreated by 22.65% to $4.6 million in 2026.
• The last three Cost of Revenue figures came in at $4.6 million (Q1 2026), $6.0 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.